[Langerhans cell histiocytosis in a child with congenital neutropenia].
Congenital neutropenia predisposes to the development of haematopoetic malignancies. We present a 3,5-year child, diagnosed with congenital neutropenia at the age of I month. The diagnosis was based on peripheral blood and bone marrow aspirate analyses, performed after the treatment of multiple axillar abscesses. Recurrent infections were treated with broad-spectrum antibiotics and leukocyte colony stimulating factors. At the age of 19 months during routine check-up the child presented with gingival hypertrophy, fragility and bleeding. The histopathological analysis of gingival biopsy was consisted with the diagnosis of Langerhans cell histiocytosis. The child was treated according to LCH protocol for therapeutic group C. After 12 months of such chemotherapy, the follow-up histopathological analysis of gingival biopsy revealed the presence of Langerhans cells, which was the indication for chemotherapy prolongation (6 additional VP courses). Chemotherapy was completed after 6 additional courses and the disease remission was confirmed by histopathological analysis of gingival biopsy. Congenital neutropenia predisposes to myeloproliferative disorders, particularly to childhood myeloblastic leukemia. Based on the presented case report we would like to emphasize the possibility of other hematological syndromes development.
Z Katedry i Kliniki Hematologii Dzieciecej i Chemioterapii w Zabrzu Slaskiej Akademii Medycznej w Katowicach.
Anna
A
Janik-Moszant
Renata
R
Tomaszewska
Aneta
A
Pobudejska
Danuta
D
Sońta-Jakimczyk
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002675:Child, Preschool; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D006801:Humans; D007223:Infant; D009503:Neutropenia / Q000151:congenital / Q000188:drug therapy / Q000503:physiopathology; D012074:Remission Induction; D013997:Time Factors